Novartis' Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes
Most major drugmakers over the past few years have fled the antibiotics space, which has been doubly hit by resistant “super bugs” and scarce innovation …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
